Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

MAB3262F

Sigma-Aldrich

Anti-BrdU Antibody, clone PRB-1, FITC conjugated

clone PRB-1, Chemicon®, from mouse

Sinónimos:

BrdU

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Código UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41

origen biológico

mouse

Nivel de calidad

conjugado

FITC conjugate

forma del anticuerpo

purified immunoglobulin

tipo de anticuerpo

primary antibodies

clon

PRB-1, monoclonal

reactividad de especies (predicha por homología)

all

fabricante / nombre comercial

Chemicon®

técnicas

flow cytometry: suitable

isotipo

IgG1

Condiciones de envío

wet ice

modificación del objetivo postraduccional

unmodified

Especificidad

Recognizes BrdU in ssDNA, free BrdU or BrdU coupled to a protein carrier. MAB3262 also reacts with iodouridine. Does not react with thymidine.

Inmunógeno

Iodouridine conjugated to ovalbumin.

Aplicación

Anti-BrdU Antibody, clone PRB-1, FITC conjugated is a Mouse Monoclonal Antibody for detection of Bromodeoxyuridine also known as BrdU & has been validated in FC.
Flow cytometry: 1:20

Optimal working dilutions must be determined by the end user.
Research Category
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair

Forma física

Purified immunoglobulin conjugated to fluorescein. Liquid in PBS with 0.05% sodium azide pH 7.4

Almacenamiento y estabilidad

Maintain at 2-8°C in undiluted aliquots up to 6 months. Protect from prolonged exposure to light.

Otras notas

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Información legal

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Código de clase de almacenamiento

12 - Non Combustible Liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

CCN1 induces hepatic ductular reaction through integrin ?v??-mediated activation of NF-?B.
Kim, KH; Chen, CC; Alpini, G; Lau, LF
The Journal of Clinical Investigation null
Yan Fan et al.
Neurotoxicity research, 38(3), 793-807 (2020-07-04)
The present study investigated the effects of forced overexpression of Phox2a/2b, two transcription factors, in the locus coeruleus (LC) of aged rats on noradrenergic and dopaminergic phenotypes in brains. Results showed that a significant increase in Phox2a/2b mRNA levels in
Songyu Li et al.
Cell death & disease, 11(4), 219-219 (2020-04-07)
DNA damage results in mutations and plays critical roles in cancer development, progression, and treatment. Targeting DNA damage response in cancers by inhibiting poly-(ADP-ribose) polymerases (PARPs) offers an important therapeutic strategy. However, the failure of PARP inhibitors to markedly benefit
Johana M Susanto et al.
International journal of oncology, 46(5), 2223-2230 (2015-02-20)
Despite incremental advances in the diagnosis and treatment for pancreatic cancer (PC), the 5‑year survival rate remains <5%. Novel therapies to increase survival and quality of life for PC patients are desperately needed. Epigenetic thera-peutic agents such as histone deacetylase
Yu Yan et al.
Oncology reports, 51(2) (2023-12-15)
The radioresistance of glioma is an important cause of treatment failure and tumor aggressiveness. In the present study, under performed with linear accelerator, the effects of 0.3 and 3.0 Gy low‑dose radiation (LDR) on the proliferation and migration of C6 glioma

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico